MONTREAL, Jan. 11 /PRNewswire-FirstCall/ -- Chronogen Inc., a drug discovery company developing therapeutics to treat age-dependent diseases announced today an agreement with Sosei Co. Ltd, (4565, Tokyo Stock Exchange MOTHERS Index)a leading Japanese biopharmaceutical company focused on drug development. Under this agreement, Chronogen Inc. will screen the library of Sosei's Drug Reprofiling Platform(R) in a variety of Chronogen's proprietary, phenotype- based, in vivo screening assays in the nematode C. elegans.
For its Drug Reprofiling Platform(R), Sosei has acquired a collection of drugs from a number of Japanese pharmaceutical companies. These drugs are safety-proven, they have been in clinical development and are either already on the Japanese market or were withdrawn from further development for reasons other than toxicity, and therefore have potential for treating disease indications other than those for which they were originally developed.
Chronogen brings specific expertise in the area of phenotype-based screening, with particular emphasis on phenotypes related to general metabolism, lipid metabolism, ROS and aging. In addition, Chronogen uses C. elegans genetics to characterize the molecular targets of gene action. Using C. elegans as a model, drug effects on anatomy, behavior, and physiology can be rapidly identified, in an efficient and cost-effective manner.
About Chronogen Inc.
Chronogen Inc., a privately-held drug discovery company, is a leader in the identification of drug targets that control the degenerative processes of aging. Using a suite of technologies including genetics and in vivo screening, the company is developing novel products to control lipid and oxidative stress levels, which are established risk factors in cardiovascular disorders. The discovery and analysis of genetic pathways that control aging in the C. elegans model has provided a platform for drug discovery that will lead to novel and efficacious drugs in significant markets including atherosclerosis, cancer, vascular complications of diabetes, ischemia/reperfusion injuries, and neurodegenerative diseases. Chronogen is headquartered in Montreal, Canada. Further information can be found at http://www.chronogen-inc.com/
About Sosei Co. Ltd
Sosei Co. Ltd. founded in 1990 by Shinichi Tamura, the ex-CEO of Genentech Japan, is a public Japanese biopharmaceutical company focused on drug development. It enriches the core product pipeline via in-licensing compounds from Western and Japanese companies, by its distinctive Drug Reprofiling Platform (DRP(R)) and through new molecular entity (NME) research programmes in collaboration with biopharmaceutical companies and universities both in Japan and the West. Sosei is also developing its own sales and marketing organization in Japan. The company is capitalizing on its extensive global network established over the past 10 years in its successful technology transfer business. For further information about Sosei, please visit http://www.sosei.com/ .